Why Employers Are Now the Front Line of Public Health

Sixty million American adults have Stage 2 hypertension and don't know it, and another 40% have no idea their cholesterol is elevated. These aren't obscure statistics for clinicians; they're the quiet drivers of the largest line items on employer health plans.

Most employers are operating with the wrong tools, and our conversation with Dr. Vin Gupta points out the issue directly. About 45% of employees aged 35 to 54 never use a covered PCP benefit. The problem isn't communication volume or benefit generosity. It's the fundamental mismatch between how employers offer health engagement and how working adults actually behave. If employers can't solve the front-door problem, downstream investment in services and therapeutics produces far less return than it should.

Three interconnected challenges define the landscape: outdated screening tools that create unnecessary friction, GLP-1 coverage decisions being made without deprescribing frameworks, and a one-size-fits-all preventive care model that precision medicine has already outpaced. A new generation of at-home diagnostics, painless lipid panels, and early-detection biomarker assays exists that most employers haven't encountered, let alone evaluated for coverage.

The goal isn't to cover more. It's to cover smarter. Identifying high-risk cohorts proactively, piloting deprescribing pathways for GLP-1 populations, and moving toward personalized screening thresholds are the levers that will actually shift outcomes. The tools exist. Most employers just haven't found them yet.

Watch Dr. Vin Gupta discuss the at-home diagnostics employers should already be evaluating and what a deprescribing framework looks like for the GLP-1 population.